Category Archives: Immunology

Immunology

expert reaction to JCVI advice on COVID-19 vaccines for the autumn booster programme – Science Media Centre

August 15, 2022

The Joint Committee on Vaccination and Immunisation (JCVI) has published its advice on which COVID-19 vaccines should be used in this years autumn booster programme.

Prof Deborah Dunn-Walters, Chair of the British Society for Immunology COVID-19 Taskforce and Professor of Immunology at the University of Surrey, said:

Over the last year, researchers have been working hard to assess how we can best protect people from COVID-19 going forwards through the use of COVID-19 booster vaccines. The results from these multiple studies have been provided to the JCVI for careful analysis to decide which vaccines should be given as a booster, when this should happen and which people should receive one.

Booster vaccines do as their name suggests they provide a boost to your immune system to increase the levels of antibodies and T cells that you have to protect you against falling seriously ill with COVID-19. Previous research shows that individuals who are older or who have a weakened immune system are particularly at risk of becoming very ill if they contract COVID-19, but that vaccination does provide significant protection to them. Therefore, it is good to see these individuals, and the people they come into regular contact with, prioritised in this booster programme.

In line with previous years, we expect to see levels of circulating SARS-CoV-2 increase during the winter months. Vaccination is still the safest and most effective way to protect yourself from becoming very ill with COVID-19. Once available, it is important to take up the offer of a COVID-19 booster vaccine if you are offered it.

Prof Beate Kampmann, Professor of Paediatric Infection & Immunity and Director of the Vaccine Centre, LSHTM, said:

Availability of a bi-valent vaccine is good news but how much of a difference it would actually make remains to be seen. The currently discussed bi-valent vaccines were developed with Omicron variant BA.1 antigens in mind, and will only deliver very partial protection against BA.4 and 5. How much difference such bi-valent vaccine can actually make remains to be seen and the bi-valent vaccines have not yet been widely tested in large heterogeneous population groups. In essence, I think it is wise not to recommend a personalized vaccination approach but to go with the wider entirely pragmatic public health message that boosters are an important intervention for the winter period and should be taken up across age groups, as recommended, with the most vulnerable to be first in line.

https://www.gov.uk/government/news/jcvi-publishes-advice-on-covid-19-vaccines-for-autumn-booster-programme

All our previous output on this subject can be seen at this weblink:

http://www.sciencemediacentre.org/tag/covid-19

Declared interests

Prof Deborah Dunn-Walters: No conflict of interests to declare.

Prof Beate Kampmann: No declarations of interest.

See the article here:
expert reaction to JCVI advice on COVID-19 vaccines for the autumn booster programme - Science Media Centre

Immunology

Degrees of the Future 2022: Immunology & Virology – Gizmodo

Immunology and virology respectively study the strengths and weaknesses of our bodys immune system, and some of the most dangerous threats to them: viruses. As new viral outbreaks emerge and familiar viruses mutate into new threats, its crucial to know how our bodies can adapt.

Five years ago, you may not have thought that much about your own immune system or the ancient, forgotten viruses thawing out of glaciers in rural Tibet. But were in a brave new world now, one where masking is more commonplace and concerns about how our bodies will handle new illnesses. Virologists and immunologists help protect humans from future pathogens. While many immunologists and virologists have PhDs in their field, theyre not necessarily required.

The Degrees of the Future 2022 top Immunology & Virology programs are:

How did Gizmodo determine this years honorees? Check out the methodology or return to the full Degrees of the Future 2022 list.

Read the rest here:
Degrees of the Future 2022: Immunology & Virology - Gizmodo

Immunology

CDI Laboratory Identifies Critical Regulators Controlling T-Cell Homeostasis Which Could Improve Cancer Therapies, Vaccines of the Future – Hackensack…

To see the Xue Lab's findings in action, watch this animation here.

A new publication in a major journal by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) could hold the key to better modulating the human immune system to fight cancer and produce vaccines of the future.

The laboratory of Hai-Hui Howard Xue at the CDI published the findings of the complex and cascading molecular interactions modulating T-cell immunology in the August issue of the journal Nature Immunology.

This is our second Nature Immunology paper from the CDI this year. The initial observation was made eight years ago, and Drs. Qiang Shan (the first author) and Weiqun Peng (our collaborators at the George Washington University) have continuously pursued mechanistic insights since then, said Xue, Ph.D., a member of the CDI.

It seeks to understand how T cell homeostasis is regulated beyond the known classical pathways, added Xue. The findings indicate that T cells can be induced to cycling while maintaining their naive status. This could change the way we harness the power of T cells heading forward.

The Xue lab in the two successive Nature Immunology publications has focused on a key dynamic of T-cell immunology: the Tcf1 transcription factor and its far-reaching molecular complexity.

Tcf1 is crucial to the immune systems memory in recognizing threats it has already faced before.

The Tcf1 transcription factor essentially preprograms a particular type of memory CD8+ T cells, called T central memory (Tcm) cells, prepping them to respond quickly and robustly to known threats, i.e., pathogens that the immune system has seen before, according to the paper earlier this year in the same journal.

That first paper pointed toward a way to improve the memory of these cells meaning potentially improving vaccines and boosting immune responses in future encounters with the same pathogens.

The new paper brings the results a step further in complexity. The scientists found that Tcf1 and Lef1 (an homologue of Tcf1) are critical in recruiting the CCCTC-binding factor (known as CTCF), a well-characterized architectural protein and a versatile transcription regulator, to key parts of the genome of the CD8+ T-cells. By so doing, Tcf1 fosters key chromatin interactions - and associated crucial gene expression programs of the CD8+ T-cells.

Xue and colleagues proved how central the Tcf1 was by knocking out the transcription factors in animal models. In so doing, it compromised the ability of CD8+ T cells to respond to two key interleukin cytokines that drive cell cycle progression to maintain a steady pool size and sustain immune competence.

By perfoming genome-wide analyses in the T cells, the scientists found significant overlap in both the Tcf1 and the CTCF binding on the CD8+ genome, thereby further demonstrating their cooperativity in multiple cellular processes.

Ultimately, they found that Tcf1 and Lef1, in working with the CTCF, provide constant supervision of this genomic architecture and confer flexibility. Together, they translate cytokine-derived signals into protein synthesis and DNA replication that underlie homeostatic proliferation of CD8+ T cells.

The prevalent overlap between Tcf1 and CTCF is unusual, and most importantly, the access of CTCF to the CD8 T-cell genome depends on Tcf1 at critical locations, said Xue. Also important to the biology side of things: both factors controlled the same set of genes regulating homeostatic proliferation.

This signifies Tcf1 and CTCF as important targets to modulate so as to amplify T cells in their nave state, which will have real implications in where science goes to harness the power of T cells in cellular therapy, Xue added.

This work has great promise, and we are thrilled to support the trailblazing work of the Xue Lab and others into new horizons of T-cell immunology, said David Perlin, Ph.D., chief scientific officer and senior vice president of the CDI.

See the article here:
CDI Laboratory Identifies Critical Regulators Controlling T-Cell Homeostasis Which Could Improve Cancer Therapies, Vaccines of the Future - Hackensack...

Immunology

Gould Fellowship in Cancer Immunology job with UNIVERSITY OF SOUTHAMPTON | 304380 – Times Higher Education

Cancer Sciences

Location: Southampton General HospitalSalary: 40,931 to 51,805Full Time Fixed TermClosing Date: Tuesday 06 September 2022Interview Date: To be confirmedReference: 1933522CM

An exciting opportunity presents itself for a new research fellowship to be established in the Centre for Cancer Immunology, within the School of Cancer Sciences at the Southampton General Hospital site. The centre, opened in 2018, builds on a 40-year history of pioneering immunology and cancer research at Southampton, and represents the first dedicated cancer immunology centre in the UK. The activities in the centre span from pioneering discovery science to applied research and pre-clinical modelling and, crucially, onto first-in-human clinical trials and beyond. The centre houses world-class research facilities, including state-of-the-art scientific laboratories and a clinical trials unit all within the same building to facilitate the most efficient translation of our findings into improved treatments for Cancer patients.

This position is associated with significant resources, up to 150k/year, to enable the appointee to develop an independent research programme. The position is expected to lead to success of the appointee in obtaining extramural funding on the pathway to independence. The appointee will be highly motivated and excited by the challenges involved in working collaboratively with the existing research groups in the centre, whilst building their own identifiable research themes. Current research programmes involve antibody engineering, immunotherapy, immune receptor biology and antigen presentation related to the treatment of cancer (www.southampton.ac.uk/youreit/meet-the-team). Ongoing activities also include mechanistic studies of therapies for autoimmunity. Research in the centre is highly interdisciplinary, and include bioinformatics, advanced microscopy and close interactions with clinicians as well as a wide group of collaborating scientists across the University (www.southampton.ac.uk/youreit/cancer-scientists)

The appointee is expected to have an outstanding research background, including high quality publications, in any area related to cancer immunology. Typically, it is expected that the appointee will have successfully completed several years of post-doctoral research, but outstanding candidates with less experience will also be considered.

The post-holder will possess relevant academic qualifications and work experience, in addition to good IT skills. Non-UK citizens are also encouraged to apply.

The position is initially fully funded for two years. Availability of funds for a third year will be dependent on satisfactory progress.

Informal queries can directed to: Professor Sally Ward (E.S.Ward@soton.ac.uk)

You should submit your completed online application form at https://jobs.soton.ac.uk. The application deadline will be midnight on the closing date sated above. If you need any assistance, please call Jane Sturgeon (Recruitment Team) on +44 (0) 23 8059 2750 or email recruitment@soton.ac.uk. Please quote reference 1933522CM on all correspondence.

Continued here:
Gould Fellowship in Cancer Immunology job with UNIVERSITY OF SOUTHAMPTON | 304380 - Times Higher Education

Immunology

Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships and Technology Awards – PR Web

Society for Immunotherapy of Cancer (SITC)

MILWAUKEE (PRWEB) August 12, 2022

The Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the recipients of the 2022 Fellowships and Technology Awards, which support the next generation of cancer immunotherapy and tumor immunology experts through dedicated funding of novel research.

Together with the immense generosity of our supporters, SITC is honored to help young investigators realize their cancer immunotherapy research dreams, said SITC President Patrick Hwu, MD. It is our hope that these young researchers turn their dreams and cure into a reality for all cancer patients.

These awards are financially supported through the Forward Fund, which was established by SITC in 2012 to stimulate the future of science, development and application of cancer immunology and immunotherapy through financially supporting its education and research. Since 2014, SITC has awarded more than $5 million in funding to deserving early career scientists in the field of cancer immunotherapy.

The 2022 SITC Fellowship and Technology Award recipients are:

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational FellowshipAward Amount: $200,000 (two-year)Awardee: Simone Minnie, PhDInstitution: Fred Hutchinson Cancer Research Center Project Title: Harnessing Treg fragility to improve anti-myeloma immune responses

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies FellowshipAward Amount: $100,000 (one-year)Awardee: John Ligon, MDInstitution: University of FloridaProject Title: Leveraging CD70 CXCR2-modified CAR T-cells for treating AML

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical FellowshipAward Amount: $100,000 (one-year)Awardee: Jonathan Chen, MD, PhDInstitution: Massachusetts General HospitalProject Title: Dissecting the tumor immunity multicellular network

SITC-Merck Cancer Immunotherapy Clinical FellowshipAward Amount: $100,000 (one-year)Awardee: Hitomi Hosoya, MD, PhDInstitution: Stanford UniversityProject Title: Cell-free DNA-based Platform to Determine Treatment Response and Resistant Mechanisms to CAR T-cell Therapy in Multiple Myeloma

SITC-Genentech Women in Cancer Immunotherapy FellowshipAward Amount: $50,000 (one-year)Awardee: Shu-chin Lai, PhDInstitution: Huntsman Cancer Institute, University of UtahProject Title: Augmenting T cell immunity to facilitate metastatic breast cancer treatment

SITC-Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy FellowshipAward Amount: $50,000 (one-year)Awardee: Mara De Martino, PhDInstitution: Weill Cornell MedicineProject Title: Targeting FASN to sensitize irradiated glioblastoma to immunotherapy

SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical FellowshipAward Amount: $40,000 (one-year)Awardee: Steven Blum, MDInstitution: Dana-Farber Cancer Institute, Massachusetts General HospitalProject Title: Distinguishing Immune-Related Adverse Events (irAEs) from Anti-Tumor Immunity

SITC-Natera ctDNA in Immunotherapy Response Monitoring Fellowship and Technology AwardAward: $40,000 and access to Nateras Signatera testing technology Awardee: Mariya Rozenblit, MDInstitution: Yale UniversityProject Title: The tumor microenvironment of triple negative breast cancers with detectable circulating tumor DNA after pembrolizumab treatment

SITC-NanoString Technologies Single Cell Biology AwardAward: Access to NanoString Technologies CosMx Spatial Molecular Imager (SMI)Awardee: Elshad Hasanov, MD, PhDInstitution: University of Texas MD Anderson Cancer CenterProject Title: CosMxing renal cell carcinoma brain metastases to decipher immune checkpoint inhibitor resistance mechanisms at single-cell and spatial context

This years SITC Forward Fund Fellowships and Technology Awards were made possible through the generosity of Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, Mallinckrodt Pharmaceuticals, Merck, Nektar Therapeutics, NanoString Technologies and Natera Technologies. The fellowship and technology award recipients will be honored during a ceremony at the societys 37th Annual Meeting at the Boston Convention and Exhibition Center in Boston, Massachusetts.

To learn more about current and past SITC Fellowship and Technology Award recipients, visit SITCs website.

About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word cure a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Share article on social media or email:

View original post here:
Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships and Technology Awards - PR Web

Immunology

Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities – Yahoo Finance

Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development

TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development.

Chemomab logo (PRNewsfoto/Chemomab Therapeutics, Ltd.)

"Chemomab is distinguished by the strength of its science, and we are fortunate these two premiere scientific and medical professionals are assuming critical roles as we progress the development of CM-101, our pipeline in a product with breakthrough potential," said Dale Pfost, PhD, Chief Executive Officer of Chemomab. "We are preparing to report topline results from our Phase 2 trial in liver fibrosis patients later this year, we are expanding our Phase 2 trial of CM-101 in primary sclerosing cholangitis, we will soon be launching a Phase 2 biological proof of concept trial in systemic sclerosis, and we are assessing potential new indications for CM-101 in other fibro-inflammatory disorders. Dr. Vaknin's more than 20 years of broad-ranging experience in immunology, bioassay development, and antibody R&D and manufacturing will be invaluable as we work to accelerate advancement of our pipeline programs."

Dr. Vaknin brings Chemomab more than two decades of biotechnology drug discovery and development experience in immunology, antibody development, translational research and bioassay development, including more than a decade in senior science roles at Compugen, Ltd. He most recently served as Director of Preclinical Bioassays, where he oversaw preclinical bioassay development and related activities, while working with computational and validation teams to support discovery of novel drug targets and biomarkers. Prior to Compugen, Dr. Vaknin served as Chief Technology Officer at Active P, where he led the development of orally available therapeutic peptides. Earlier in his career, he served as External Scientific Consultant for the Department of Neurobiology at Israel's Weizmann Institute of Science. Dr. Vaknin holds a PhD in immunology and a BA in life sciences from The Hebrew University of Jerusalem, where he also received an MBA in finance.

Story continues

Dr. Pfost continued, "Dr. Crater's extensive background in medical affairs and clinical trial design and execution across a broad range of therapeutic indications will be instrumental as we ramp up our clinical activities. She has highly relevant experience leading clinical research programs in immuno-inflammation and orphan diseases. Her decade as a front-line physician gives her a first-hand appreciation for the essential roles of patients and physicians in the successful development of new therapies. I am delighted to welcome Ilan and Chris to the Chemomab senior team at this exciting time in our evolution."

Dr. Crater has served as a medical monitor, safety physician, therapeutic expert and study director in all phases of clinical development, including extensive experience in data quality and safety monitoring. Her career spans working in-house at pharmaceutical and biotechnology firms, as well as at major clinical research organizations (CROs). Previously Dr. Crater served as Senior Clinical Trial Physician at Bristol-Myers Squibb, where she was responsible for the review and interpretation of clinical data while contributing to strategic decisions on clinical study design and asset advancement. Dr. Crater also served in senior clinical development roles with PRA Health Sciences and PAREXEL International. Earlier in her career, Dr. Crater worked as an internal medicine physician. She received an MD degree from the University of Tennessee and holds a BS from Rhodes College. Dr. Crater is board certified in Internal Medicine.

About Chemomab Therapeutics

Chemomabis a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022. For more information, visitchemomab.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab's current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including: risks related to Chemomab's ability to effectively implement the revised clinical strategy and its ability to achieve the anticipated results; risks related to the projections and associated benefits in pursuing the contemplated changes to the clinical strategy; risks associated with the ongoing transitions of certain of our executive officers; the uncertain and time-consuming regulatory approval process; risks related to Chemomab's ability to correctly manage its operating expenses and its expenses; Chemomab's plans to develop and commercialize its product candidates, focusing on CM-101; the timing of initiation of Chemomab's planned clinical trials; the timing of the availability of data from Chemomab's clinical trials including any potential delays associated with Chemomab's contemplated revised clinical strategy; the timing of any planned investigational new drug application or new drug application; Chemomab's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Chemomab's product candidates; Chemomab's commercialization, marketing and manufacturing capabilities and strategy; Chemomab's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. Additional risks and uncertainties relating to Chemomab's and its business can be found under the caption "Risk Factors" and elsewhere in Chemomab's filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except to the extent required by applicable law.

Contacts:

Media:

Investor Relations:

Barbara Lindheim

Irina Koffler

Chemomab Therapeutics

LifeSci Advisors, LLC

Consulting Vice President

Phone: +1-917-734-7387

Investor & Public Relations,

ir@chemomab.com

Strategic Communications

Phone: +1-917-355-9234

barbara@chemomab.com

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-adds-highly-experienced-executives-further-strengthening-its-rd-and-clinical-capabilities-301604869.html

SOURCE Chemomab Therapeutics, Ltd.

See original here:
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities - Yahoo Finance

Immunology

Professor Dr.Tzenios was inducted into the hall of Fame of the Medical Research Council (FMRC) USA by honoring him with a distinguished FMRC…

Professor Dr. Nikolaos Tzenios,Ph.D., FRSPH, FRSM, FAAMFM, FWAMS, FMRC, AcIASS, mRSB, DABAAHP|, a University Professor of Public Health,had been inducted into the hall of fame by honoring him with theFellowship of theMedical Research Council (FMRC) for hisremarkable contribution to medical research. His international journal publications have received international acclaim and significantly impacted the global research community.

This is to certify that renowned researcher Professor Dr.Nikolaos Tzenios is hereby recognized and honored as aFellow of Medical Research Council (FMRC).The designated fellow is elected to the esteemed grade for theexceptional achievements in pursuit of advanced studies &research in his work and remarkable contributions to CancerResearch.Dr. Vivek Dubey, (MS, Ph.D., University of Wisconsin)Secretary Open Association of Research Society, Delaware.

Professor Dr. Nikolaos Tzenios research articles with several citations show his profound understanding of research methodology and display his keen insight into the subtle aspects of his field. They were selected for publication after passing through the exhaustive peer-review parameters and approved by an editorial board comprising eminent researchers and scientists.

Dr. Nikolaos Tzenios shows the originality of thought and delves into hitherto untouched areas.

TheFellowship of theMedical Research CouncilIt is not only an award but also a membership granted to individuals which the Open Association of Research Society Judges feel that the Scientist has made a substantial contribution to the improvement of Cancer Research.

The designated Fellows are the most eminent scientists, engineers, and technologists worldwide. The credentials of Fellow designation signify that the researcher has gained knowledge of fundamental and high-level concepts, is a subject matter expert, is proficient in an expertise course covering the professional code of conduct and follows recognized standards of practice.

Professor Tzenios communicates his ideas with spontaneous ease and shows academic commitment and research aptitude, which give us enough ground to believe that he has the potential to render yeomanly services in the academic field. This gives us enough ground to believe his knowledge will benefit the upcoming research scholars.

Almost all the leading indexing organizations have indexed Global Journals Organisation journals. It publishes journals in forty disciplines bringing out around three hundred research articles per month read by about two hundred thousand readers in different parts of the world. Research contribution comes from renowned researchers and scientists from universities of one hundred fifty-seven countries. The organization has to its credit the publication of more than eighteen thousand research works.

Dr. Nikolaos Tzenios the Senior Executive Vice-President of the World Academy of Medical (https://www.linkedin.com/in/nicolastzenios) is a member of the Scientific board of the European Medical Association, a Fellow of The Royal Society for Public Health (UK), a Fellow of The Royal Society of Medicine (UK), a Fellow of the World Academy of Medical Sciences, a Fellow of the American Academy of Anti-Aging Medicine.

Dr. Tzenios is also a Member of the American Academy of Regenerative Medicine, a Member The European Academy of Allergy and Clinical Immunology, a Member American Academy of Allergy, Asthma & Immunology (AAAAI), and Member the American Federation for Medical Research, a Member of the Royal Society of Biology (U.K.) and an ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences.

Media ContactCompany Name: Release NewsContact Person: Andrew BraithwaiteEmail: Send EmailPhone: +44 (0) 161 818 6487Country: United StatesWebsite: https://release-news.com/

Original post:
Professor Dr.Tzenios was inducted into the hall of Fame of the Medical Research Council (FMRC) USA by honoring him with a distinguished FMRC...

Immunology

Serum Calprotectin Levels Linked to Subclinical Carotid Atherosclerosis in Patients With Psoriatic Arthritis – Rheumatology Network

In patients with psoriatic arthritis (PsA), serum calprotectin levels are associated with the presence of carotid plaques, according to a study published in Frontiers in Immunology.1

In PsA patients, serum calprotectin level was independently associated with the presence of carotid plaques, probably involving platelet and endothelial cells activation, Isaac Cheng, PhD, of The Chinese University of Hong Kong in Shatin, China, and colleagues, wrote. Moreover, subclinical carotid atherosclerosis was associated with the inflammatory burden (as reflected by the disease duration) in these patients.

While the association between PsA and increased cardiovascular (CV) disease risk is well established, only limited data is available on the underlying mechanisms.

This cross-sectional study included 78patients (52.6% male, mean age 52 years) with PsA but without CV disease. Calprotectin levels in serum were quantified and high-resolution ultrasound was used to determine carotid intima-media thickness and the presence of plaque.

Of the patients, 37.2% had carotid plaques. Serum calprotectin level was significantly higher in the group with carotid plaques compared with those without carotid plaques (721.3 ng/ml vs 564.6 ng/ml, P = 0.005). Serum calprotectin level correlated with PsA disease duration and mean carotid intima-media thickness.

Least absolute shrinkage and selection operator regression was performed to screen out 19 predictive variables including age, gender, traditional CV risk factors, medication use, clinical features and disease activity. Ln-calprotectin (OR: 3.38, 95% CI [1.37, 9.47]; P = 0.026) and PsA disease duration (1.09, 95% CI [1.01, 1.18]; P = 0.013) were statistically significant in predicting carotid plaque.

Investigators developed a nomogram for discriminating the presence of carotid plaque, which they said was an easy reference for clinical practice, with good accuracy, sensitivity and specificity (AUC 0.744, sensitivity 65%, specificity 79%). They concluded that serum calprotectin level may be a useful biomarker associated with a high inflammatory burden and the presence of subclinical carotid atherosclerosis in patients with PsA.

A limitation of the study was that most of the patients had low disease activity, thus the results may not be applicable to patients with moderate or high disease activity.

Reference:

Cheng IT, Meng H, Li M, et al. Serum Calprotectin Level Is Independently Associated With Carotid Plaque Presence in Patients With Psoriatic Arthritis.Front Med (Lausanne). 2022;9:932696. Published 2022 Jul 8. doi:10.3389/fmed.2022.932696

See the rest here:
Serum Calprotectin Levels Linked to Subclinical Carotid Atherosclerosis in Patients With Psoriatic Arthritis - Rheumatology Network

Immunology

Senior Lecturer, Bacteriology job with UNIVERSITY OF MELBOURNE | 304525 – Times Higher Education

Location:ParkvilleRole type:Full time; ContinuingFaculty:Faculty of Medicine, Dentistry and Health SciencesDepartment/School:Department of Microbiology and ImmunologySalary:Level C $135,032 $155,698 p.a. plus 17% super

The University of Melbourne would like to acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated, the Wurundjeri and Boon Wurrung Peoples, the Yorta Yorta Nation, and the Dja Dja Wurrung People. We acknowledge that the land on which we meet and learn was the place of age-old ceremonies, celebration, initiation, and renewal, and that the local Aboriginal Peoples have had and continue to have a unique role in the life of these lands.

About The Department of Microbiology & Immunology

TheDepartment of Microbiology & Immunologyis one of three departments within the School of Biomedical Sciences in the Faculty of Medicine, Dentistry, and Health Sciences and is also an integral component of the Peter Doherty Institute for Infection and Immunity (http://www.doherty.unimelb.edu.au).

It accommodates nearly 40 research laboratories which span areas including bacteriology, virology, immunology, pathology, and cancer biology, a team of dedicated teaching specialists, and the Microbiology Diagnostic Unit, a public health microbiology diagnostic laboratory.

About the Role

As part of the departments strategic plan to build and strengthen its bacteriology discipline, we are seeking to fill two teaching and research positions; in addition to the Senior Lecturer, applications for Associate Professor / Professor in Bacteriology will be opening soon.

Along with an independent research program, you will make a major contribution to teaching in the field of microbiology as well as the associated curriculum, policy development, and administrative tasks. This will include responsibilities in specific undergraduate subjects including course coordination and the planning, implementation, and delivery of teaching activities as well as assessment approaches.

Further responsibilities include:

Located within the Parkville precinct, you will have access to world-leading infrastructure at the Bio21 Institute, as well as the superior equipment and resources of the Peter Doherty Institute.

About You

This role is well positioned to form productive linkages with the numerous research and health centres that are collocated within the precinct and as such, you will utilise your strong interpersonal skills to collaborate within the Department, the Doherty Institute, and the wider University precinct.

You are a natural leader and have an established track record in bacteriology, with clear potential to build a prominent and productive research program that complements the Department and Institute strengths in infection and immunity. Applicants with research programs that use innovative approaches to study host-pathogen interactions are particularly encouraged to apply.

You will also have:

To ensure the University continues to provide a safe environment for everyone, this position requires the incumbent to hold a current and valid Working with Children Check.

About the University

The University of Melbourne is consistently ranked amongst the leading universities in the world. We are proud of our people, our commitment to research and teaching excellence, and our global engagement.

Benefits of Working with Us

In addition to having the opportunity to grow and be challenged, and to be part of a vibrant campus life, our people enjoy a range of rewarding benefits:

To find out more, visithttps://about.unimelb.edu.au/careers/staff-benefits.

Be Yourself

We value the unique backgrounds, experiences and contributions that each person brings to our community and encourage and celebrate diversity. First Nations people, those identifying as LGBTQIA+, females, people of all ages, with disabilities and culturally and linguistically diverse people are encouraged to apply. Our aim is to create a workforce that reflects the community in which we live.

Join Us!

If you feel this role is right for you, please submit your application including a brief cover letter, your resume and your responses against the selection criteria^ (found in the Position Description) for the role.

^For information to help you with compiling short statements to answer the selection criteria and competencies, please go tohttp://about.unimelb.edu.au/careers/selection-criteria

We are dedicated to ensuring barrier free and inclusive practices to recruit the most talented candidates. If you require any reasonable adjustments with the recruitment process, please contact us athr-talent@unimelb.edu.au.

Position Description:0039842_Senior Lecturer_Bacteriology_PD.pdf

Applications close:21 SEPT 2022 11:55 PMAUS Eastern Standard Time

More:
Senior Lecturer, Bacteriology job with UNIVERSITY OF MELBOURNE | 304525 - Times Higher Education

Immunology

Immunology Drugs Market worth $183.49 billion by 2030 – Exclusive Report by InsightAce Analytic – PR Newswire UK

JERSEY CITY, N.J., July 18, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the 'Global Immunology Drugs Market By Drug Class (Monoclonal antibodies, Fusion Proteins, Immunosuppressants, Polyclonal antibodies, and Other Drug classes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Disease Indications (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, and Other disease Indication)) - Trends, Industry Competition Analysis, Revenue and Forecast To 2030.'

According to the latest research by InsightAce Analytic, global immunology drugs market is valued at US$ 88.85 Billion in 2021, and it is expected to reach US$ 183.49 Billion by 2030, with a CAGR of 8.7% during the forecast period of 2022-2030.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1328

Immunology Drugs are substances and drugs that modify the immunological response by stimulating or suppressing the immune system. They are used to treat or prevent a variety of autoimmune and immunological conditions, as well as to combat infections. Increased awareness of immunological illnesses in both emerging and developed nations and the growing prevalence of immunological disorders induced by environmental factors are significant drivers propelling the expansion of the global market.

There is a sizable patient population with autoimmune illnesses due to a variety of environmental factors, such as infections, stress, dietary components, gut dysbiosis, and exposure to hazardous substances. With the high demand for these medications globally, market participants are actively investing in their research and development. Additionally, during the projected period, increased autoimmune illness awareness in both developed and developing countries and prospective pipeline candidates are predicted to propel market expansion. The Immunology Drugs drug market is anticipated to rise as a result of patients with poor prognoses. Trial data shows that therapeutic effects last for an extended period even after the tumor has been reduced after the immune system has been primed to attack cancer Immunology Drugs.

Despite the fact that immunological illnesses are growing more prevalent in significant regions, the market's expansion is constrained over the projected period by a number of factors. High costs and adverse side effects are two factors expected to limit the market. Biologics are expensive due in part to the high cost of manufacturing facilities and the substantial expenditure in research and development needed to get biologics through the FDA approval and clinical trial procedures.

The market for Immunology Drugs is anticipated to be dominated by North America. Due to its well-developed healthcare infrastructure, higher prevalence of chronic diseases, and comparatively higher diagnosis and treatment rates, the United States now dominates the global market. Increasing patient demand for treatment options and increased public awareness are expected to boost demand throughout the projected period. Prominent players in the immunology drugs market are Eli Lilly Company, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer, Novartis, Astellas, Alector, ImmuNext, Merck sharp & Dohme Corp., UCB SA, and other prominent players.

Key Developments In The Market:

Curious about this latest version of the report? Enquiry Before Buying athttps://www.insightaceanalytic.com/enquiry-before-buying/1328

Global Immunology Drugs Market, by by Drug Class, 2022-2030 (Value US$ Bn)

Global Immunology Drugs Market, by Distribution Channel, 2022-2030 (Value US$ Bn)

Global Immunology Drugs Market, by Disease Indications, 2022-2030 (Value US$ Bn)

Rheumatoid Arthritis

Global Immunology Drugs Market, by Region, 2022-2030 (Value US$ Bn)

North America Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Europe Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Asia Pacific Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Latin America Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Middle East & Africa Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Why should buy this report:

For More Customization at https://www.insightaceanalytic.com/customisation/1328

Other Related Reports Published by InsightAce Analytic:

Global Neuropsychiatric Drugs Market

Global Neuroimmunology Drugs Market

Global Neurodegenerative Disease Market

Global Preclinical Oncology Models Market

Global Immuno-Oncology Cell Therapy Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:InsightAce Analytic Pvt. Ltd.Tel.: +1 551 226 6109Email:info@insightaceanalytic.comSite Visit:www.insightaceanalytic.comFollow Us on LinkedIn @bit.ly/2tBXsgSFollow Us OnFacebook@bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

SOURCE InsightAce Analytic Pvt. Ltd.

Originally posted here:
Immunology Drugs Market worth $183.49 billion by 2030 - Exclusive Report by InsightAce Analytic - PR Newswire UK